Physician profile
Basim Abdelkarim
NPI 1932217544
$3,794.02
in general payments reported to CMS, 2019-2025
24 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $115 · 2021: $528 · 2022: $318 · 2023: $478 · 2024: $1,112 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.78 | 2019-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $278.73 | 2019-2024 | Eohilia |
| Redhill Biopharma INC. | $254.17 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Janssen Biotech, INC. | $235.81 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.23 | 2020-2025 | Xifaxan, Relistor |
| Allergan, INC. | $153.68 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $131.59 | 2021-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $129.49 | 2023-2025 | Voquezna |
| Revance Therapeutics, INC. | $122.36 | 2024 | Daxxify |
| Pfizer INC. | $118.67 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $118.45 | 2020-2023 | |
| Genzyme Corporation | $103.46 | 2024-2025 | |
| Gilead Sciences, INC. | $100.01 | 2023-2025 | |
| Ardelyx, INC. | $95.12 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $67.64 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $49.95 | 2019-2021 | |
| Celgene Corporation | $45.82 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $34.37 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $32.57 | 2019-2023 | Linzess |
| Vivus LLC | $20.37 | 2025 | Pancreaze |
| Daiichi Sankyo INC. | $18.69 | 2021 | |
| Evoke Pharma, INC. | $17.24 | 2022 | |
| W. L. Gore & Associates, INC. | $15.61 | 2023 | Gore Cardioform Septal Occluder |
| Boston Scientific Corporation | $15.21 | 2025 | Agile Esophageal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basim Abdelkarim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.